Cure My Disease

Don't miss your cure!

 Log in / Sign up

Psoriasis drug stelara under safety watch in kids

NCT ID NCT03218488

Ongoing Disease control Sponsor: Janssen-Cilag International NV Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 07, 2026 · Updated 3 times

Summary

This study follows 135 children aged 6 to 17 with moderate to severe plaque psoriasis who are already starting or have recently started treatment with ustekinumab (Stelara). Researchers are monitoring for serious side effects like infections, cancer, and autoimmune issues, as well as effects on growth and puberty. The goal is to understand the long-term safety of this drug in young patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
ustekinumab (Stelara)
What this could lead to
If successful, this study could confirm that ustekinumab is safe for long-term use in children with psoriasis, helping doctors manage the disease more confidently.
What could go wrong
This is an observational study, not a treatment trial, so it won't test if the drug works better than other options. It only tracks safety, and results may not apply to all children.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PSORIASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PSORIASIS

Contacts and locations

Locations

  • Andreas Sygros Hospital

    Athens, 16121, Greece

  • Bispebjerg Hospital

    Copenhagen, NV 2400, Denmark

  • CH Victor Dupouy Argenteuil

    Argenteuil, 95107, France

  • CHRU Besancon Hopital Jean Minjoz

    Besançon, 25030, France

  • CHU Saint Etienne Hopital Nord

    Saint-Etienne, 42055, France

  • CHU de Liège - Domaine Universitaire du Sart Tilman

    Liège, 4000, Belgium

  • FSBI 'Scientific Centre of Children Health' of the Russian Academy of Medical Sciences

    Moscow, 119991, Russia

  • Gemeinschaftspraxis Dres. Quist

    Mainz, 55128, Germany

  • Gentofte Herlev Hospital

    Hellerup, 2800, Denmark

  • Grand Hôpital de Charleroi

    Loverval, 6280, Belgium

  • Great Ormond Street Hospital

    London, WC1N 3JH, United Kingdom

  • Groupe Hospitalier Pellegrin CHU de Bordeaux

    Bordeaux, 33076, France

  • Hopital Necker Enfants Malades

    Paris, 75743, France

  • ICH Hopital A. Morvan

    Brest, 29609, France

  • Kinderspital Zürich

    Zurich, 8032, Switzerland

  • Le Bateau Blanc

    Martigues, 13500, France

  • Llc Ultramed

    Omsk, 644024, Russia

  • Moscow Research-Practical Center of Dermatovenerology and Cosmetology

    Moscow, 119049, Russia

  • Oslo universitetssykehus HF, Rikshospitalet

    Oslo, 0027, Norway

  • Praxis Dr. med. Beate Schwarz - Germany

    Langenau, 89129, Germany

  • Radboudumc

    Nijmegen, 6525 EX, Netherlands

  • Saint-Petersburg State Pediatric Medical Academy of RosZdrav

    Saint Petersburg, 194353, Russia

  • Salford Royal Hospital

    Salford, M6 8HD, United Kingdom

  • UCL Hopital Saint-Luc

    Brussels, 1200, Belgium

  • UZ Leuven

    Leuven, 3000, Belgium

  • Uniklinik Graz

    Graz, 8036, Austria

  • Universitatsmedizin der Johannes Gutenberg Universitat Mainz

    Mainz, 55131, Germany

  • University Hospital for Skin and Venereal Diseases

    Thessaloniki, 54 643, Greece

  • University Hospital of Wales

    Cardiff, CF14 4XW, United Kingdom

  • Whipps Cross University Hospital

    London, E11 1NR, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.